Oxygen Biotherapeutics announces its expanded product development plan

Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) announced its expanded product development plan.

The new clinical development pipeline now encompasses seven indications for the Oxycyte(TM) emulsion: Traumatic Brain Injury, Carbon Monoxide Poisoning, Surgical Iatrogenic Air Embolism, Spinal Cord Injury, Organ Preservation, Decompression Sickness, and Sickle Cell Crisis. Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier.

In the topical product area, the first use of the Dermacyte Gel is for a cosmetic line that is now available for pre-orders via the BuyDermacyte.com website with product shipment expected in about four weeks. The company plans to expand the cosmetic line into additional skin care products during 2010.

The topical pipeline includes six additional topical indications in development for the Oxycyte Gel. These include treatment for Wounds, Burns, Acne, Rosacea, Cell Treatment after Radiation Therapy, and Erectile Dysfunction.

Two other indications in development are based on Oxycyte compound in it's clear liquid form. They are the liquid ventilation device VitaVent, and Deep Immersion Fluorocarbon Treatment for severe burns.

"We have put together a product development plan that no longer depends on just one drug use indication with all of the associated risks and uncertainties. We now have four strategic pillars: Cosmetic with Dermacyte and related products, Topical Applications including wound care, Clinical Applications including TBI, and Devices including our VitaVent invention," said Company Chairman and CEO Chris J. Stern.

"Our clinical and topical development lines now include fifteen important potential applications. Before the end of the year, we plan to file an IND with the U.S. FDA for Oxycyte emulsion as a treatment for Carbon Monoxide poisoning. In addition, we plan to expand our cosmetic line rapidly in 2010. It's all part of our strategy to become a multi-product company with a clearly visible path for growth."

Slides outlining the development plan were presented at the company's shareholder meeting on Oct. 19, 2009. A replay of the webcast of that meeting may be found on the investor relations section of the company website. The replay will be archived for 90 days.